Investigation of Encephalopathy Caused by Shiga Toxin 2c-Producing Escherichia coli Infection in Mice

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Amran, Muhammad Yunus ^a,e   Fujii, Jun ^a   Suzuki, Satoshi O ^a   Kolling, Glynis L ^b   Villanueva, Sharon Y A M ^a   Kainuma, Mosaburo ^c   Kobayashi, Hideyuki ^d   Kameyama, Hideko ^a   Yoshida, Shin Ichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF VIRGINIA   (United States)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e HASANUDDIN UNIVERSITY   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; CASPASE 3; GLYCOSPHINGOLIPID GLOBOTRIAOSYLCERAMIDE SYNTHETASE; MESSENGER RNA; SHIGA TOXIN 2C; SYNTHETASE; UNCLASSIFIED DRUG; VEROTOXIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BLOOD BRAIN BARRIER; BRAIN DISEASE; CELL ACTIVATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME LOCALIZATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; IN SITU HYBRIDIZATION; MEDULLA OBLONGATA; MICROGLIA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOTONEURON; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RETICULAR FORMATION; SPINAL CORD; UPREGULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; AQUAPORIN 4; ASTROCYTES; AZITHROMYCIN; BLOOD-BRAIN BARRIER; CASPASE 3; ENDOTHELIAL CELLS; ESCHERICHIA COLI INFECTIONS; FEMALE; MEDULLA OBLONGATA; MICE; MICE, INBRED ICR; NEURONS; NEUROTOXICITY SYNDROMES; SHIGA-TOXIGENIC ESCHERICHIA COLI;

EID: 84874911217     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058959     Document Type: Article

References (49)

1. Karch H, Denamur E, Dobrindt U, Finlay BB, Hengge R, et al. (2012) The enemy within us: lessons from the 2011 European Escherichia coli O104:H4 outbreak. EMBO Mol Med 4: 841-848.
2. Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, et al. (2011) Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 365: 709-717.
3. Greinacher A, Friesecke S, Abel P, Dressel A, Stracke S, et al. (2011) Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 378: 1166-1173.
4. Matano S, Inamura K, Konishi M, Okumura T, Kawai H, et al. (2012) Encephalopathy, disseminated intravascular coagulation, and hemolytic-uremic syndrome after infection with enterohemorrhagic Escherichia coli O111. J Infect Chemother 18: 558-564.
5. Rooney JC, Anderson RM, Hopkins IJ, (1971) Clinical and pathological aspects of central nervous system involvement in the haemolytic uraemic syndrome. Aust Paediatr J 7: 28-33.
6. Siegler RL, (1995) The hemolytic uremic syndrome. Pediatr Clin North Am 42: 1505-1529.
7. Upadhyaya K, Barwick K, Fishaut M, Kashgarian M, Siegel NJ, (1980) The importance of nonrenal involvement in hemolytic-uremic syndrome. Pediatrics 65: 115-120.
8. Fujii J, Kita T, Yoshida S, Takeda T, Kobayashi H, et al. (1994) Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice. Infect Immun 62: 3447-3453.
9. Fujii J, Kinoshita Y, Kita T, Higure A, Takeda T, et al. (1996) Magnetic resonance imaging and histopathological study of brain lesions in rabbits given intravenous verotoxin 2. Infect Immun 64: 5053-5060.
10. Steinborn M, Leiz S, Rudisser K, Griebel M, Harder T, et al. (2004) CT and MRI in haemolytic uraemic syndrome with central nervous system involvement: distribution of lesions and prognostic value of imaging findings. Pediatr Radiol 34: 805-810.
11. Yamada Y, Fujii J, Murasato Y, Nakamura T, Hayashida Y, et al. (1999) Brainstem mechanisms of autonomic dysfunction in encephalopathy-associated Shiga toxin 2 intoxication. Ann Neurol 45: 716-723.
12. O'Brien AD, Holmes RK, (1987) Shiga and Shiga-like toxins. Microbiol Rev 51: 206-220.
13. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, et al. (1988) Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 171: 45-50.
14. Fraser ME, Fujinaga M, Cherney MM, Melton-Celsa AR, Twiddy EM, et al. (2004) Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J Biol Chem 279: 27511-27517.
15. Strockbine NA, Jackson MP, Sung LM, Holmes RK, O'Brien AD, (1988) Cloning and sequencing of the genes for Shiga toxin from Shigella dysenteriae type 1. J Bacteriol 170: 1116-1122.
16. Tesh VL, Burris JA, Owens JW, Gordon VM, Wadolkowski EA, et al. (1993) Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun 61: 3392-3402.
17. Siegler RL, Obrig TG, Pysher TJ, Tesh VL, Denkers ND, et al. (2003) Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Pediatr Nephrol 18: 92-96.
18. Lingwood CA, Law H, Richardson S, Petric M, Brunton JL, et al. (1987) Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem 262: 8834-8839.
19. Louise CB, Obrig TG, (1991) Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun 59: 4173-4179.
20. Louise CB, Obrig TG, (1992) Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of Shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infect Immun 60: 1536-1543.
21. Furukawa K, Yokoyama K, Sato T, Wiels J, Hirayama Y, et al. (2002) Expression of the Gb3/CD77 synthase gene in megakaryoblastic leukemia cells: implication in the sensitivity to verotoxins. J Biol Chem 277: 11247-11254.
22. Bauwens A, Bielaszewska M, Kemper B, Langehanenberg P, von Bally G, et al. (2011) Differential cytotoxic actions of Shiga toxin 1 and Shiga toxin 2 on microvascular and macrovascular endothelial cells. Thromb Haemost 105: 515-528.
23. Fujii J, Matsui T, Heatherly DP, Schlegel KH, Lobo PI, et al. (2003) Rapid apoptosis induced by Shiga toxin in HeLa cells. Infect Immun 71: 2724-2735.
24. Fujii J, Wood K, Matsuda F, Carneiro-Filho BA, Schlegel KH, et al. (2008) Shiga toxin 2 causes apoptosis in human brain microvascular endothelial cells via C/EBP homologous protein. Infect Immun 76: 3679-3689.
25. Obata F, Tohyama K, Bonev AD, Kolling GL, Keepers TR, et al. (2008) Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons. J Infec Dis 198: 1398-1406.
26. Landoni VI, Schierloh P, de Campos Nebel M, Fernandez GC, Calatayud C, et al. (2012) Shiga toxin 1 induces on lipopolysaccharide-treated astrocytes the release of tumor necrosis factor-alpha that alter brain-like endothelium integrity. PLoS Pathog 8: e1002632.
27. Lucero MS, Mirarchi F, Goldstein J, Silberstein C, (2012) Intraperitoneal administration of Shiga toxin 2 induced neuronal alterations and reduced the expression levels of aquaporin 1 and aquaporin 4 in rat brain. Microb Pathog 53: 87-94.
28. Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, et al. (1999) Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 52: 357-362.
29. Yoshimura K, Fujii J, Taniguchi H, Yoshida S, (1999) Chemotherapy for enterohemorrhagic Escherichia coli O157:H infection in a mouse model. FEMS Immunol Med Microbiol 26: 101-108.
30. Fujii J, Kinoshita Y, Matsukawa A, Villanueva SY, Yutsudo T, et al. (2009) Successful steroid pulse therapy for brain lesion caused by Shiga toxin 2 in rabbits. Microb Pathog 46: 179-184.
31. Ohara T, Kojio S, Taneike I, Nakagawa S, Gondaira F, et al. (2002) Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response. Antimicrob Agents Chemother 46: 3478-3483.
32. Myhal ML, Laux DC, Cohen PS, (1982) Relative colonizing abilities of human fecal and K 12 strains of Escherichia coli in the large intestines of streptomycin-treated mice. Eur J Clin Microbiol 1: 186-192.
33. Matsuoka T, Suzuki SO, Suenaga T, Iwaki T, Kira J, (2011) Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients. Brain Pathol 21: 516-532.
34. Smith MC, Sephel GC, Woodward SC, (1993) Spreadsheet templates for calculating precision according to NCCLS (National Committee for Clinical Laboratory Standards) guidelines. MLO Med Lab Obs 25: 67-69.
35. Wiels J, Fellous M, Tursz T, (1981) Monoclonal antibody against a Burkitt lymphoma-associated antigen. Proc Natl Acad Sci USA 78: 6485-6488.
36. Okuda T, Tokuda N, Numata S, Ito M, Ohta M, et al. (2006) Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J Biol Chem 281: 10230-10235.
37. Magnus T, Rother J, Simova O, Meier-Cillien M, Repenthin J, et al. (2012) The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain 135: 1850-1859.
38. Goldstein J, Loidl CF, Creydt VP, Boccoli J, Ibarra C, (2007) Intracerebroventricular administration of Shiga toxin type 2 induces striatal neuronal death and glial alterations: an ultrastructural study. Brain Res 1161: 106-115.
39. Papadopoulos MC, Manley GT, Krishna S, Verkman AS, (2004) Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J 18: 1291-1293.
40. Verkman AS, Binder DK, Bloch O, Auguste K, Papadopoulos MC, (2006) Three distinct roles of aquaporin-4 in brain function revealed by knockout mice. Biochim Biophys Acta 1758: 1085-1093.
41. Forsyth KD, Simpson AC, Fitzpatrick MM, Barratt TM, Levinsky RJ, (1989) Neutrophil-mediated endothelial injury in haemolytic uraemic syndrome. Lancet 2: 411-414.
42. Arthur FE, Shivers RR, Bowman PD, (1987) Astrocyte-mediated induction of tight junctions in brain capillary endothelium: an efficient in vitro model. Brain Res 433: 155-159.
43. Hamm S, Dehouck B, Kraus J, Wolburg-Buchholz K, Wolburg H, et al. (2004) Astrocyte mediated modulation of blood-brain barrier permeability does not correlate with a loss of tight junction proteins from the cellular contacts. Cell Tissue Res 315: 157-166.
44. Farina C, Aloisi F, Meinl E, (2007) Astrocytes are active players in cerebral innate immunity. Trends Immunol 28: 138-145.
45. Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, et al. (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201: 195-200.
46. Pehar M, Cassina P, Vargas MR, Castellanos R, Viera L, et al. (2004) Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem 89: 464-473.
47. Zhang Q, Donohue-Rolfe A, Krautz-Peterson G, Sevo M, Parry N, et al. (2009) Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. J Infect Dis 199: 486-493.
48. Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, et al. (2012) Risk Factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: A multivariable analysis. Clin Infect Dis 55: 33-41.
49. Nitschke M, Sayk F, Hartel C, Roseland RT, Hauswaldt S, et al. (2012) Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 307: 1046-1052.